You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
In a study published last month, Mammoth demonstrated the technology's sensitivity, specificity, and speed compared to PCR-based COVID-19 testing.
The company said its test, which provides results in approximately one hour, is the first instance of CRISPR technology being authorized by the FDA.
The platform can detect a single virus in more than 1,000 samples at a time or more than 160 viruses, including SARS-CoV-2, in a small number of samples.
The researchers said their assay can be run in 30 to 45 minutes, with 95 percent positive predictive agreement and 100 percent negative predictive agreement.
The deal is part of a wider collaboration between the companies to develop molecular diagnostic tests using their respective platforms.
The company is in talks with potential partners in the US and China to validate the assay on clinical samples and deploy it at a large scale.
Two new grants are helping the company develop its SHERLOCK and INSPECTR technologies as the basis for creating innovative diagnostics.
The Broad Institute spinout will develop its CRISPR-based Sherlock platform for battlefield-ready diagnostics for infectious disease agents.
The company said its test is faster, more precise, and cheaper than the current gold standard Cepheid GeneXpert test.
The company, founded in May 2018 and headquartered in Guangzhou in southern China, has developed a CRISPR-based rapid diagnostics platform for pathogen detection.